Anixa Biosciences subsidiary awarded patent for CAR-T cancer treatment Anixa announced that the USPTO has issued a Notice of Allowance for the first patent covering Anixa subsidiary Certainty Therapeutics’ CAR-T cancer treatment technology. The patent is assigned to The Wistar Institute and Anixa Biosciences’ majority-owned subsidiary, Certainty Therapeutics, is the exclusive, world-wide licensee.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.